The Community Guide

- gsearch

Search Results

Narrow Results:

2024 1
2019 1
2018 1
2017 1
2016 1
2006 1

IPVS Policy Committee GarlandSuzanne MabcStanleyMargaretmMoscickiAnna-BarbaranWooYin LingoBhatlaNeerjapChanKaren L.qPalefskyJoelrGiulianoAnna RsKaufmannAndreasgde SanjoseSilviaiBrothertonJulia M.L.tuFeldmanSarahv 1

Australia 2

Journal Article 6

1 - 6 of 6 Results

Refine Results

Refine Results:

Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes

CITE Title : Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes Personal Author(s) : Mesher, David;Soldan, Kate;Lehtinen, Matti;Beddows, Simon;Brisson, Marc;Brotherton, Julia M.L.;Chow, Eric P.F.;Cummings, Teresa;Drolet, Mélanie;Fairley, Christopher K.;Garland, Suzanne M.;Kahn, Jessica A.;Kavanagh, Kimberley;Markowitz, Lauri;Pollock, Kevin G.;Söderlund-Strand, Anna;Sonnenberg, Pam;Tabrizi, Sepehr N.;Tanton, Clare;Unger, Elizabeth;Thomas, Sara L.; Published Date : Oct 2016 Source : Emerg Infect Dis. 22(10):1732-1740. URL : https://stacks.cdc.gov/view/cdc/42762 Mesher, David et al. (2016). Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes. 22(10). Mesher, David et al. "Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes" 22, no. 10 (2016) Mesher, David et al. "Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes" vol. 22, no. 10, 2016 Export RIS Citation Information.

:

Mesher, David ;

Soldan, Kate

Oct 2016 | Emerg Infect Dis. 22(10):1732-1740.

:

We analyzed human papillomavirus (HPV) prevalences during prevaccination and postvaccination periods to consider possible changes in nonvaccine HPV ge...
Symptoms, Sites, and Significance of Mycoplasma genitalium in Men Who Have Sex with Men

CITE Title : Symptoms, Sites, and Significance of Mycoplasma genitalium in Men Who Have Sex with Men Personal Author(s) : Read, Tim R.H.;Murray, Gerald L.;Danielewski, Jennifer A.;Fairley, Christopher K.;Doyle, Michelle;Worthington, Karen;Su, Jenny;Mokany, Elisa;Tan, L.T.;Lee, David;Vodstrcil, Lenka A.;Chow, Eric P.F.;Garland, Suzanne M.;Chen, Marcus Y.;Bradshaw, Catriona S.; Published Date : Apr 2019 Source : Emerg Infect Dis. 25(4):719-727 URL : https://stacks.cdc.gov/view/cdc/77146 Read, Tim R.H. et al. (2019). Symptoms, Sites, and Significance of Mycoplasma genitalium in Men Who Have Sex with Men. 25(4). Read, Tim R.H. et al. "Symptoms, Sites, and Significance of Mycoplasma genitalium in Men Who Have Sex with Men" 25, no. 4 (2019) Read, Tim R.H. et al. "Symptoms, Sites, and Significance of Mycoplasma genitalium in Men Who Have Sex with Men" vol. 25, no. 4, 2019 Export RIS Citation Information.

:

Read, Tim R.H. ;

Murray, Gerald L.

Apr 2019 | Emerg Infect Dis. 25(4):719-727

:

During 2016-2017, we tested asymptomatic men who have sex with men (MSM) in Melbourne, Australia, for Mycoplasma genitalium and macrolide resistance m...
Azithromycin Failure in Mycoplasma genitalium Urethritis

CITE Title : Azithromycin Failure in Mycoplasma genitalium Urethritis Personal Author(s) : Bradshaw, Catriona S.;Jensen, Jorgen S.;Tabrizi, Sepehr N.;Read, Timothy R.H.;Garland, Suzanne M.;Hopkins, Carol A.;Moss, Lorna M.;Fairley, Christopher K.; Published Date : Jul 2006 Source : Emerg Infect Dis. 12(7):1149-1152. URL : https://stacks.cdc.gov/view/cdc/16171 Bradshaw, Catriona S. et al. (2006). Azithromycin Failure in Mycoplasma genitalium Urethritis. 12(7). Bradshaw, Catriona S. et al. "Azithromycin Failure in Mycoplasma genitalium Urethritis" 12, no. 7 (2006) Bradshaw, Catriona S. et al. "Azithromycin Failure in Mycoplasma genitalium Urethritis" vol. 12, no. 7, 2006 Export RIS Citation Information.

:

Bradshaw, Catriona S. ;

Jensen, Jorgen S.

Jul 2006 | Emerg Infect Dis. 12(7):1149-1152.

:

We report significant failure rates (28%, 95% confidence interval 15%-45%) after administering 1 g azithromycin to men with Mycoplasma genitalium-posi...
Use of Pristinamycin for Macrolide-Resistant Mycoplasma genitalium Infection

CITE Title : Use of Pristinamycin for Macrolide-Resistant Mycoplasma genitalium Infection Personal Author(s) : Read, Tim R.H.;Jensen, Jørgen S.;Fairley, Christopher K.;Grant, Mieken;Danielewski, Jennifer A.;Su, Jenny;Murray, Gerald L.;Chow, Eric P.F.;Worthington, Karen;Garland, Suzanne M.;Tabrizi, Sepehr N.;Bradshaw, Catriona S.; Published Date : Feb 2018 Source : Emerg Infect Dis. 24(2):328-335. URL : https://stacks.cdc.gov/view/cdc/51376 Read, Tim R.H. et al. (2018). Use of Pristinamycin for Macrolide-Resistant Mycoplasma genitalium Infection. 24(2). Read, Tim R.H. et al. "Use of Pristinamycin for Macrolide-Resistant Mycoplasma genitalium Infection" 24, no. 2 (2018) Read, Tim R.H. et al. "Use of Pristinamycin for Macrolide-Resistant Mycoplasma genitalium Infection" vol. 24, no. 2, 2018 Export RIS Citation Information.

:

Read, Tim R.H. ;

Jensen, Jørgen S.

Feb 2018 | Emerg Infect Dis. 24(2):328-335.

:

High levels of macrolide resistance and increasing fluoroquinolone resistance are found in Mycoplasma genitalium in many countries. We evaluated prist...
IPVS POLICY STATEMENT ON HPV NUCLEIC ACID TESTING guidance for those utilising/considering HPV as primary precancer screening: Quality Assurance and Quality Control issues

CITE Title : IPVS POLICY STATEMENT ON HPV NUCLEIC ACID TESTING guidance for those utilising/considering HPV as primary precancer screening: Quality Assurance and Quality Control issues Personal Author(s) : Garland, Suzanne M.;Iftner, Thomas;Cuschieri, Kate;Kaufmann, Andreas M;Arbyn, Marc;de Sanjose, Silvia;Poljak, Mario;Dillner, Joakim;Unger, Elizabeth R.; Corporate Authors(s) : IPVS Policy Committee GarlandSuzanne MabcStanleyMargaretmMoscickiAnna-BarbaranWooYin LingoBhatlaNeerjapChanKaren L.qPalefskyJoelrGiulianoAnna RsKaufmannAndreasgde SanjoseSilviaiBrothertonJulia M.L.tuFeldmanSarahv Published Date : 2-2023 Source : J Clin Virol. 159:105349 URL : https://stacks.cdc.gov/view/cdc/162398 Garland, Suzanne M. et al. (2024). IPVS POLICY STATEMENT ON HPV NUCLEIC ACID TESTING guidance for those utilising/considering HPV as primary precancer screening: Quality Assurance and Quality Control issues. 159 Garland, Suzanne M. et al. "IPVS POLICY STATEMENT ON HPV NUCLEIC ACID TESTING guidance for those utilising/considering HPV as primary precancer screening: Quality Assurance and Quality Control issues" 159 (2024) Garland, Suzanne M. et al. "IPVS POLICY STATEMENT ON HPV NUCLEIC ACID TESTING guidance for those utilising/considering HPV as primary precancer screening: Quality Assurance and Quality Control issues" vol. 159, 2024 Export RIS Citation Information.

:

Garland, Suzanne M. ;

Iftner, Thomas

2-2023 | J Clin Virol. 159:105349

:

We advise that only clinically validated HPV assays which have fulfilled internationally accepted performance criteria be used for primary cervical sc...
Increasing Macrolide and Fluoroquinolone Resistance in Mycoplasma genitalium

CITE Title : Increasing Macrolide and Fluoroquinolone Resistance in Mycoplasma genitalium Personal Author(s) : Murray, Gerald L.;Bradshaw, Catriona S.;Bissessor, Melanie;Danielewski, Jennifer;Garland, Suzanne M.;Jensen, Jørgen S.;Fairley, Christopher K.;Tabrizi, Sepehr N.; Published Date : May 2017 Source : Emerg Infect Dis. 23(5):809-812. URL : https://stacks.cdc.gov/view/cdc/45630 Murray, Gerald L. et al. (2017). Increasing Macrolide and Fluoroquinolone Resistance in Mycoplasma genitalium. 23(5). Murray, Gerald L. et al. "Increasing Macrolide and Fluoroquinolone Resistance in Mycoplasma genitalium" 23, no. 5 (2017) Murray, Gerald L. et al. "Increasing Macrolide and Fluoroquinolone Resistance in Mycoplasma genitalium" vol. 23, no. 5, 2017 Export RIS Citation Information.

:

Murray, Gerald L. ;

Bradshaw, Catriona S.

May 2017 | Emerg Infect Dis. 23(5):809-812.

:

Escalating resistance to azithromycin and moxifloxacin is being reported for Mycoplasma genitalium in the Asia-Pacific region. Analyzing 140 infection...